Jane Street
RLMD icon

Jane Street’s Relmada Therapeutics RLMD Stock Holding History

Jane Street’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-102,200
Closed -$3.78M – 9989
2022
Q3 		$3.78M Buy
+102,200
New +$2.83M ﹤0.01% 3068
2021
Q3 		– Sell
-21,900
Closed -$701K – 10596
2021
Q2 		$701K Buy
+21,900
New +$761K ﹤0.01% 6588

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Jane Street's RLMD Position: Q1 2026 in Review

Jane Street reduced its Relmada Therapeutics (RLMD) stake by 18% in Q1 2026, selling an estimated $232K and leaving 221,969 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #5577.

Jane Street first reported a position in RLMD in Q1 2020 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Jane Street held 221,969 shares of Relmada Therapeutics worth $1.54M as of Q1 2026.
  • Jane Street sold 49,140 Relmada Therapeutics shares in Q1 2026, an estimated $232K.
  • Relmada Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5577 holding.
  • Jane Street first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.